{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:11:46Z","timestamp":1791583906793,"version":"4.3.4"},"reference-count":150,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.jaut.2019.102364","type":"journal-article","created":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T19:55:42Z","timestamp":1575921342000},"page":"102364","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":144,"special_numbering":"C","title":["Sj\u00f6gren's syndrome: Old and new therapeutic targets"],"prefix":"10.1016","volume":"110","author":[{"given":"Clio P.","family":"Mavragani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haralampos M.","family":"Moutsopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2019.102364_bib1","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1503\/cmaj.122037","article-title":"Sj\u00f6gren syndrome review","volume":"186","author":"Mavragani","year":"2014","journal-title":"Can. Med. Assoc. J."},{"key":"10.1016\/j.jaut.2019.102364_bib2","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1191\/0961203306lu2290rr","article-title":"The role of epithelial cells in the initiation and perpetuation of autoimmune lesions: lessons from Sjogren's syndrome (autoimmune epithelitis)","volume":"15","author":"Mitsias","year":"2006","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2019.102364_bib3","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1006\/clin.1994.1123","article-title":"Sj\u00f6gren\u2019s syndrome: autoimmune epithelitis","volume":"72","author":"Moutsopoulos","year":"1994","journal-title":"Clin. Immunol. Immunopathol."},{"key":"10.1016\/j.jaut.2019.102364_bib4","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/ncprheum0165","article-title":"The management of Sj\u00f6gren\u2019s syndrome","volume":"2","author":"Mavragani","year":"2006","journal-title":"Nat. Clin. Pract. Rheumatol."},{"key":"10.1016\/j.jaut.2019.102364_bib5","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1146\/annurev-med-043015-123313","article-title":"Mechanisms and new strategies for primary sj\u00f6gren\u2019s syndrome","volume":"68","author":"Mavragani","year":"2017","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.jaut.2019.102364_bib6","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/rheumatology\/34.4.326","article-title":"Cytokine mRNA expression in the labial salivary gland tissues from patients with primary Sj\u00f6gren\u2019s syndrome","volume":"34","author":"Boumba","year":"1995","journal-title":"Br. J. Rheumatol."},{"key":"10.1016\/j.jaut.2019.102364_bib7","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1136\/ard.2009.115378","article-title":"Cytokines in Sjogren's syndrome: potential therapeutic targets","volume":"69","author":"Roescher","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102364_bib8","first-page":"970","article-title":"Salivary cytokine profiles in primary Sj\u00f6gren\u2019s syndrome differ from those in non-sj\u00f6gren sicca in terms of TNF-\u03b1 levels and Th-1\/Th-2 ratios","volume":"29","author":"Kang","year":"2011","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jaut.2019.102364_bib9","series-title":"StatPearls, StatPearls Publishing","article-title":"Biologic response modifiers (BRMs)","author":"Sapkota","year":"2019"},{"key":"10.1016\/j.jaut.2019.102364_bib10","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/art.20146","article-title":"Inefficacy of infliximab in primary sj\u00f6gren\u2019s syndrome: results of the randomized, controlled trial of remicade in primary sj\u00f6gren\u2019s syndrome (TRIPSS)","volume":"50","author":"Mariette","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.102364_bib11","first-page":"96","article-title":"Etanercept in the treatment of patients with primary Sj\u00f6gren\u2019s syndrome: a pilot study","volume":"31","author":"Zandbelt","year":"2004","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jaut.2019.102364_bib12","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1002\/art.20299","article-title":"Etanercept in Sj\u00f6gren\u2019s syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial","volume":"50","author":"Sankar","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.102364_bib13","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1136\/ard.2007.077891","article-title":"Lack of efficacy of etanercept in Sj\u00f6gren syndrome correlates with failed suppression of tumour necrosis factor \u03b1 and systemic immune activation","volume":"67","author":"Moutsopoulos","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102364_bib14","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1002\/art.23062","article-title":"Augmented interferon-\u03b1 pathway activation in patients with Sj\u00f6gren\u2019s syndrome treated with etanercept","volume":"56","author":"Mavragani","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.102364_bib15","article-title":"Emerging roles for chemokines and cytokines as orchestrators of immunopathology in Sj\u00f6gren\u2019s syndrome","author":"Blokland","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2019.102364_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-9255-4-5","article-title":"The role of the purinergic P2X7receptor in inflammation","volume":"4","author":"Lister","year":"2007","journal-title":"J. Inflamm."},{"key":"10.1016\/j.jaut.2019.102364_bib17","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.cell.2016.03.046","article-title":"Inflammasome complexes: emerging mechanisms and effector functions","volume":"165","author":"Rathinam","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.jaut.2019.102364_bib18","doi-asserted-by":"crossref","first-page":"16626","DOI":"10.1074\/jbc.M117.790741","article-title":"P2X7 receptor antagonism prevents IL-1 release from salivary epithelial cells and reduces inflammation in a mouse model of autoimmune exocrinopathy","volume":"292","author":"Khalafalla","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jaut.2019.102364_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030123","article-title":"Interleukin-1 inhibition and fatigue in primary sj\u00f6gren\u2019s syndrome - a double blind, randomised clinical trial","volume":"7","author":"Norheim","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jaut.2019.102364_bib20","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/acr.22720","article-title":"Fatigue in primary sj\u00f6gren\u2019s syndrome: clinical, laboratory, psychometric, and biologic associations","volume":"68","author":"Karageorgas","year":"2016","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.jaut.2019.102364_bib21","article-title":"Topical administration of interleukin-1 receptor antagonist as a therapy for aqueous-deficient dry eye in autoimmune disease","volume":"19","author":"Vijmasi","year":"2013","journal-title":"Mol. Vis."},{"key":"10.1016\/j.jaut.2019.102364_bib22","series-title":"New Insights and Long-Term Safety of Tocilizumab in Rheumatoid Arthritis","first-page":"195","author":"Jones","year":"2018"},{"key":"10.1016\/j.jaut.2019.102364_bib23","series-title":"Large-vessel Giant Cell Arteritis\u00a0: Diagnosis , Monitoring and Management","first-page":"32","author":"Koster","year":"2018"},{"key":"10.1016\/j.jaut.2019.102364_bib24","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/annrheumdis-2017-211682","article-title":"Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis\u00a0: results from the open-label period of a phase II randomised controlled trial ( faSScinate )","volume":"77","author":"Khanna","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102364_bib25","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.pediatrneurol.2017.05.015","article-title":"First pediatric patient with neuromyelitis optica and sj\u00f6gren syndrome successfully treated with tocilizumab","volume":"73","author":"Marino","year":"2017","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.jaut.2019.102364_bib26","series-title":"Neuromyelitis Optica Spectrum Disorder Complicated with Sjogren Syndrome Successfully Treated with Tocilizumab\u00a0: A Case Report","first-page":"1","volume":"vol. 7595","author":"Komai","year":"2013"},{"key":"10.1016\/j.jaut.2019.102364_bib27","series-title":"Tocilizumab for Refractory Organising Pneumonia Associated with Sj\u00f6gren \u2019 S Disease","first-page":"2014","author":"Justet","year":"2015"},{"issue":"suppl 10","key":"10.1016\/j.jaut.2019.102364_bib28","article-title":"IL-6 receptor inhibition in primary sj\u00f6gren syndrome : results from a randomized multicenter academic double blind placebo-controlled trial of tocilizumab in 110 patients [abstract]","volume":"71","author":"Felten","year":"2019","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.102364_bib29","first-page":"577","volume":"vol. 48","author":"Mucke","year":"1998"},{"key":"10.1016\/j.jaut.2019.102364_bib30","first-page":"567","article-title":"Iguratimod for the treatment of rheumatoid arthritis in Japan","volume":"11","author":"Yamaguchi","year":"2015","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.jaut.2019.102364_bib31","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1111\/1756-185X.13633","article-title":"Efficacy and safety of iguratimod plus corticosteroid as bridge therapy in treating mild IgG4-related diseases: a prospective clinical trial","volume":"22","author":"Zhang","year":"2019","journal-title":"Int. J. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102364_bib32","article-title":"Therapeutic efficacy of iguratimod in patients with primary Sjogren's syndrome - ACR meeting abstracts","volume":"18","author":"Zhang","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2019.102364_bib33","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2019-eular.7472","article-title":"Ab0465 efficacy and safety of iguratimod in patients with primary sjogren syndrome: a follow-up study","volume":"78","author":"Gao","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102364_bib34","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12876-018-0858-z","article-title":"Suspected drug-induced liver injury associated with iguratimod: a case report and review of the literature","volume":"18","author":"Li","year":"2018","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.jaut.2019.102364_bib35","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1056\/NEJM197907053010102","article-title":"Immune interferon in the circulation of patients with autoimmune disease","volume":"301","author":"Hooks","year":"1979","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2019.102364_bib36","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jaut.2015.07.002","article-title":"Type I and II interferon signatures in Sjogren's syndrome pathogenesis: contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis","volume":"63","author":"Nezos","year":"2015","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2019.102364_bib37","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/BOR.0b013e328349fd30","article-title":"Activation of the type I interferon pathway in primary Sj\u00f6gren\u02bcs syndrome","volume":"23","author":"Vakaloglou","year":"2011","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.jaut.2019.102364_bib38","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1586\/1744666X.2014.876364","article-title":"Type I IFN signature in primary Sj\u00f6gren\u2019s syndrome patients","volume":"10","author":"Brkic","year":"2014","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.jaut.2019.102364_bib39","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/annrheumdis-2012-201381","article-title":"Prevalence of interferon type I signature in CD14 monocytes of patients with Sj\u00f6gren\u2019s syndrome and association with disease activity and BAFF gene expression","volume":"72","author":"Brkic","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102364_bib40","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/art.39204","article-title":"Molecular subsetting of interferon pathways in Sj\u00f6gren\u2019s syndrome","volume":"67","author":"Hall","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2019.102364_bib41","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1073\/pnas.0510837103","article-title":"Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren's syndrome","volume":"103","author":"Gottenberg","year":"2006","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jaut.2019.102364_bib42","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1146\/annurev-pathol-020117-043952","article-title":"Type I interferons in autoimmune disease","volume":"14","author":"Crow","year":"2019","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.jaut.2019.102364_bib43","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1002\/art.39795","article-title":"Expression of long interspersed nuclear element 1 retroelements and induction of type I interferon in patients with systemic autoimmune disease","volume":"68","author":"Mavragani","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2019.102364_bib44","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.0001-2815.2004.00290.x","article-title":"The LILR family: modulators of innate and adaptive immune pathways in health and disease","volume":"64","author":"Brown","year":"2004","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.jaut.2019.102364_bib45","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1365-2567.2009.03097.x","article-title":"Regulation of T-cell immunity by leucocyte immunoglobulin-like receptors: innate immune receptors for self on antigen-presenting cells","volume":"127","author":"Anderson","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.jaut.2019.102364_bib46","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.0105-2896.2009.00867.x","article-title":"Signaling and ligand interaction of ILT7: receptor-mediated regulatory mechanisms for plasmacytoid dendritic cells","volume":"234","author":"Cao","year":"2010","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.jaut.2019.102364_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089414","article-title":"Effect of immunoglobin-like transcript 7 cross-linking on plasmacytoid dendritic cells differentiation into antigen-presenting cells","volume":"9","author":"Tavano","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jaut.2019.102364_bib48","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nri1604","article-title":"Mechanisms of type-I- and type-II-interferon-mediated signalling","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jaut.2019.102364_bib49","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1177\/0961203316678675","article-title":"Safety, pharmacokinetics, and pharmacodynamics of RSLV-132, an RNase-Fc fusion protein in systemic lupus erythematosus: a randomized, double-blind, placebo-controlled study","volume":"26","author":"Burge","year":"2017","journal-title":"Lupus"},{"issue":"177","key":"10.1016\/j.jaut.2019.102364_bib50","first-page":"1","article-title":"Op0202 effect of rslv-132 on fatigue in patients with primary sj\u00f6gren\u2019S syndrome \u2013 results of a phase Ii randomised, double-blind, placebo-controlled, proof of concept study","author":"Fisher","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102364_bib51","doi-asserted-by":"crossref","first-page":"R155","DOI":"10.1186\/ar3895","article-title":"Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus","volume":"14","author":"Sacre","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2019.102364_bib52","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJM199101173240303","article-title":"A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus","volume":"324","author":"Canadian Hydroxychloroquine Study Group","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2019.102364_bib53","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.2014.7682","article-title":"Effects of hydroxychloroquine on symptomatic improvement in primary Sj\u00f6gren syndrome: the JOQUER randomized clinical trial","volume":"312","author":"Gottenberg","year":"2014","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.jaut.2019.102364_bib54","article-title":"Hydroxychloroquine treatment downregulates systemic interferon activation in primary Sj\u00f6gren\u2019s syndrome in the JOQUER randomized trial","author":"Bodewes","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2019.102364_bib55","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti\u2013interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2019.102364_bib56","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/ar625","article-title":"Systemic lupus erythematosus and the type I interferon system","volume":"5","author":"R\u00f6nnblom","year":"2003","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2019.102364_bib57","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jaut.2018.02.001","article-title":"TBK1: a key regulator and potential treatment target for interferon positive Sjogren's syndrome, systemic lupus erythematosus and systemic sclerosis","volume":"91","author":"Bodewes","year":"2018","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2019.102364_bib58","first-page":"473","article-title":"Cathepsin S inhibitors as novel immunomodulators","volume":"6","author":"Thurmond","year":"2000","journal-title":"Curr. Opin. Investig. Drugs (London, England?"},{"key":"10.1016\/j.jaut.2019.102364_bib59","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1172\/JCI0214682","article-title":"Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity","volume":"110","author":"Saegusa","year":"2002","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.jaut.2019.102364_bib60","series-title":"Longitudinal Analysis of Tear Cathepsin S Activity Levels in Male Non-obese Diabetic Mice Suggests its Potential as an Early Stage Biomarker of Sj\u00f6gren\u2019s Syndrome, Biomarkers","author":"Janga","year":"2018"},{"key":"10.1016\/j.jaut.2019.102364_bib61","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1002\/art.38633","article-title":"Tear cathepsin s as a candidate biomarker for sj\u00f6gren\u2019s syndrome","volume":"66","author":"Hamm-Alvarez","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2019.102364_bib62","first-page":"1","article-title":"Differential effects of specific cathepsin S inhibition in biocompartments from patients with primary Sj\u00f6gren syndrome","volume":"2","author":"Hargreaves","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2019.102364_bib63","doi-asserted-by":"crossref","first-page":"9559","DOI":"10.1038\/s41598-019-45966-7","article-title":"Inhibition of cathepsin S reduces lacrimal gland inflammation and increases tear flow in a mouse model of sj\u00f6gren\u2019s syndrome","volume":"9","author":"Klinngam","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jaut.2019.102364_bib64","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.immuni.2016.04.017","article-title":"Co-stimulatory and Co-inhibitory pathways in autoimmunity","volume":"44","author":"Zhang","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.jaut.2019.102364_bib65","doi-asserted-by":"crossref","first-page":"102333","DOI":"10.1016\/j.jaut.2019.102333","article-title":"Immune checkpoint molecules. Possible future therapeutic implications in autoimmune diseases","volume":"104","author":"Huang","year":"2019","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2019.102364_bib66","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.4049\/jimmunol.180.6.3815","article-title":"A novel B7-2 (CD86) splice variant with a putative negative regulatory role","volume":"180","author":"Kapsogeorgou","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2019.102364_bib67","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1046\/j.1365-2249.2000.01121.x","article-title":"Treatment with anti-CD86 costimulatory molecule prevents the autoimmune lesions in murine Sjogren's syndrome (SS) through up-regulated Th2 response","volume":"119","author":"Saegusa","year":"2000","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jaut.2019.102364_bib68","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/1074-7613(94)90071-X","article-title":"CTLA-4 can function as a negative regulator of T cell activation","volume":"1","author":"Walunas","year":"1994","journal-title":"Immunity"},{"key":"10.1016\/j.jaut.2019.102364_bib69","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1136\/annrheumdis-2013-204653","article-title":"Abatacept treatment reduces disease activity in early primary Sj\u00f6gren\u2019s syndrome (open-label proof of concept ASAP study)","volume":"73","author":"Meiners","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102364_bib70","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/14397595.2014.951144","article-title":"Efficacy and safety of abatacept for patients with Sj\u00f6gren\u2019s syndrome associated with rheumatoid arthritis: rheumatoid Arthritis with Orencia Trial toward Sj\u00f6gren\u2019s syndrome Endocrinopathy (ROSE) trial\u2014an open-label, one-year, prospective study\u2014interim an","volume":"25","author":"Tsuboi","year":"2015","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.jaut.2019.102364_bib71","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1002\/acr.22052","article-title":"Evaluation of histologic, serologic, and clinical changes in response to abatacept treatment of primary sj\u00f6gren\u2019s syndrome: a pilot study","volume":"65","author":"Adler","year":"2013","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.jaut.2019.102364_bib72","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/art.40059","article-title":"Enhanced Bruton's tyrosine kinase activity in peripheral blood B lymphocytes from patients with autoimmune disease","volume":"69","author":"Corneth","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2019.102364_bib73","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1002\/art.40165","article-title":"Attenuation of follicular helper T cell\u2013dependent B cell hyperactivity by abatacept treatment in primary sj\u00f6gren\u2019s syndrome","volume":"69","author":"Verstappen","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2019.102364_bib74","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1080\/14397595.2017.1349234","article-title":"Diffusion-weighted magnetic resonance imaging of parotid glands before and after abatacept therapy in patients with Sj\u00f6gren\u2019s syndrome associated with rheumatoid arthritis: utility to evaluate and predict response to treatment","volume":"28","author":"Takahashi","year":"2018","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.jaut.2019.102364_bib75","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3109\/14397595.2016.1158773","article-title":"Effectiveness of abatacept for patients with Sj\u00f6gren\u2019s syndrome associated with rheumatoid arthritis. An open label, multicenter, one-year, prospective study: ROSE (Rheumatoid Arthritis with Orencia Trial toward Sj\u00f6gren\u2019s syndrome Endocrinopathy) trial","volume":"26","author":"Tsuboi","year":"2016","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.jaut.2019.102364_bib76","first-page":"1","volume":"vol. 93","author":"Spijkervet","year":"2019"},{"key":"10.1016\/j.jaut.2019.102364_bib77","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1126\/science.1160062","article-title":"Supporting online material CTLA-4 control over Foxp3 + regulatory T cell function","volume":"322","author":"Wing","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.jaut.2019.102364_bib78","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3000116","article-title":"Inducing CTLA-4-dependent immune regulation by selective CD28 blockade promotes regulatory T cells in organ transplantation","volume":"2","author":"Poirier","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jaut.2019.102364_bib79","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jaut.2013.11.003","article-title":"Differentiation of follicular helper T cells by salivary gland epithelial cells in primary Sj\u00f6gren\u2019s syndrome","volume":"51","author":"Gong","year":"2014","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2019.102364_bib80","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1002\/art.40479","article-title":"Brief report: a randomized, double-blind, parallel-group, placebo-controlled, multiple-dose study to evaluate AMG 557 in patients with systemic lupus erythematosus and active","volume":"70","author":"Cheng","year":"2018","journal-title":"Lupus Arthritis, Arthritis Rheumatol."},{"issue":"suppl 10","key":"10.1016\/j.jaut.2019.102364_bib81","article-title":"A phase 2a study of MEDI5872 (AMG557), a fully human anti-ICOS ligand monoclonal antibody in patients with primary sj\u00f6gren\u2019s syndrome [abstract]","volume":"71","author":"Mariette","year":"2019","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.102364_bib82","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.addr.2018.12.005","article-title":"Targeting the CD40-CD40L pathway in autoimmune diseases: humoral immunity and beyond","volume":"141","author":"Karnell","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jaut.2019.102364_bib83","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jaut.2006.02.002","article-title":"Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases","volume":"26","author":"Goules","year":"2006","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2019.102364_bib84","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/sji.12121","article-title":"Upregulation of membrane-bound CD40L on CD4+T cells in women with primary sj\u00f6gren\u2019s syndrome","volume":"79","author":"Belkhir","year":"2014","journal-title":"Scand. J. Immunol."},{"issue":"Suppl 10","key":"10.1016\/j.jaut.2019.102364_bib85","first-page":"69","article-title":"The novel anti-CD40 monoclonal antibody CFZ533 shows beneficial effects in patients with primary sj\u00f6gren\u2019s syndrome: a phase IIa double-blind, placebo-controlled randomized trial - ACR meeting abstracts","volume":"69","author":"Fisher B","year":"2017","journal-title":"Arthritis Rheum."},{"issue":"760","key":"10.1016\/j.jaut.2019.102364_bib86","first-page":"2","article-title":"Subcutaneous dosing OF the novel ANTI-CD40 antibody iscalimab achieves target drug exposure and clinical efficacy IN primary SJ\u00d6GREN\u2019S syndrome; results OF a phase IIA randomised open label two arm parallel group trial","author":"Fisher","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102364_bib87","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/annrheumdis-2018-213929","article-title":"Blockade of CD40-CD154 pathway interactions suppresses ectopic lymphoid structures and inhibits pathology in the NOD\/ShiLtJ mouse model of Sj\u00f6gren\u2019s syndrome","volume":"78","author":"Wieczorek","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102364_bib88","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3389\/fimmu.2018.00952","article-title":"LFA-1 in T Cell migration and differentiation","volume":"9","author":"Walling","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2019.102364_bib89","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.exer.2003.10.024","article-title":"ICAM-1 expression predisposes ocular tissues to immune-based inflammation in dry eye patients and Sj\u00f6grens syndrome-like MRL\/lpr mice","volume":"78","author":"Gao","year":"2004","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.jaut.2019.102364_bib90","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1046\/j.1365-2249.2001.01500.x","article-title":"Activation of epithelial and myoepithelial cells in the salivary glands of patients with Sj\u00f6gren\u2019s syndrome: high expression of intercellular adhesion molecule-1 (ICAM.1) in biopsy specimens and cultured cells","volume":"124","author":"Kapsogeorgou","year":"2001","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jaut.2019.102364_bib91","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1365-2249.1995.tb03790.x","article-title":"Prevention of adoptive transfer of murine Sj\u00f6gren\u2019s syndrome into severe combined immunodeficient (SCID) mice by antibodies against intercellular adhesion molecule-1 (ICAM-1) and lymphocyte function-associated antigen-1 (LFA-1)","volume":"102","author":"Hayashi","year":"1995","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jaut.2019.102364_bib92","article-title":"Suppression of Th1-mediated keratoconjunctivitis sicca by Lifitegrast","volume":"00","author":"Guimaraes de Souza","year":"2018","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.jaut.2019.102364_bib93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12013-008-9036-1","article-title":"The BLyS family: toward a molecular understanding of B cell homeostasis","volume":"53","author":"Treml","year":"2009","journal-title":"Cell Biochem. Biophys."},{"key":"10.1016\/j.jaut.2019.102364_bib94","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1084\/jem.190.11.1697","article-title":"Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations","volume":"190","author":"Mackay","year":"1999","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jaut.2019.102364_bib95","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1136\/ard.62.2.168","article-title":"The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sj\u00f6gren\u2019s syndrome","volume":"62","author":"Mariette","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102364_bib96","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jaut.2013.04.005","article-title":"B-cell activating factor genetic variants in lymphomagenesis associated with primary Sj\u00f6gren\u2019s syndrome","volume":"51","author":"Nezos","year":"2014","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2019.102364_bib97","series-title":"BLyS Upregulation in Sj\u00f6gren \u2019 S Syndrome Associated with Lymphoproliferative Disorders , Higher ESSDAI Score and B-Cell Clonal Expansion in the Salivary Glands","first-page":"276","author":"Quartuccio","year":"2013"},{"key":"10.1016\/j.jaut.2019.102364_bib98","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1002\/art.39231","article-title":"A BAFF receptor His159Tyr mutation in Sj\u00f6gren\u2019s syndrome-related lymphoproliferation","volume":"67","author":"Papageorgiou","year":"2015","journal-title":"Arthritis & Rheumatol. (Hoboken, N.J.)."},{"key":"10.1016\/j.jaut.2019.102364_bib99","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/annrheumdis-2013-203991","article-title":"Efficacy and safety of belimumab in primary Sj\u00f6gren\u2019s syndrome: results of the BELISS open-label phase II study","volume":"74","author":"Mariette","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102364_bib100","first-page":"2249","article-title":"Efficacy and safety of belimumab given for 12 months in primary Sj\u00f6gren\u2019s syndrome: the BELISS open-label phase II study","volume":"54","author":"De Vita","year":"2015","journal-title":"Rheumatology (United Kingdom)"},{"key":"10.1016\/j.jaut.2019.102364_bib101","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1093\/rheumatology\/kev005","article-title":"Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjogren's syndrome","volume":"54","author":"Pontarini","year":"2015","journal-title":"Rheumatology (United Kingdom)"},{"key":"10.1016\/j.jaut.2019.102364_bib102","unstructured":"L. Quartuccio, S. Salvin, L. Corazza, S. Gandolfo, M. Fabris, S. De Vita, Efficacy of belimumab and targeting of rheumatoid factor-positive B-cell expansion in Sj\u00f6gren\u2019s syndrome: follow-up after the end of the phase II open-label BELISS study., Clin. Exp. Rheumatol.. 34 (n.d.) 311\u2013314."},{"key":"10.1016\/j.jaut.2019.102364_bib103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-015-0750-y","article-title":"Low numbers of blood and salivary natural killer cells are associated with a better response to belimumab in primary Sj\u00f6gren\u2019s syndrome: results of the BELISS study","volume":"17","author":"Seror","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2019.102364_bib104","first-page":"719","article-title":"Type I interferon signature may influence the effect of belimumab on immunoglobulin levels, including rheumatoid factor in Sj\u00f6gren\u2019s syndrome","author":"Quartuccio","year":"2017","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jaut.2019.102364_bib105","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1080\/19420862.2019.1624463","article-title":"Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease","volume":"11","author":"Benschop","year":"2019","journal-title":"MAbs"},{"issue":"300","key":"10.1016\/j.jaut.2019.102364_bib106","first-page":"3","article-title":"THU0313\u2005Double-Blind, randomized study of VAY736 single dose treatment in patients with primary sj\u00f6gren\u2019s syndrome (PSS)","volume":"75","author":"D\u00f6rner","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102364_bib107","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/annrheumdis-2018-214720","article-title":"Treatment of primary sj\u00f6gren\u2019s syndrome with ianalumab (vay736) targeting b cells by baff receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity","volume":"78","author":"D\u00f6rner","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"suppl 10","key":"10.1016\/j.jaut.2019.102364_bib108","volume":"71","author":"Smolen","year":"2019","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.102364_bib109","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.3389\/fimmu.2019.01990","article-title":"Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders","volume":"10","author":"Kaegi","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2019.102364_bib110","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1136\/ard.2007.083865","article-title":"Reduction of fatigue in Sj\u00f6gren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study","volume":"67","author":"Dass","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102364_bib111","doi-asserted-by":"crossref","first-page":"233","DOI":"10.7326\/M13-1085","article-title":"Treatment of primary sj\u00f6gren syndrome with rituximab","volume":"160","author":"Devauchelle-Pensec","year":"2014","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jaut.2019.102364_bib112","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/art.27314","article-title":"Effectiveness of rituximab treatment in primary Sj\u00f6gren\u2019s syndrome: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Meijer","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.102364_bib113","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/art.40093","article-title":"Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary sj\u00f6gren\u2019s syndrome","volume":"69","author":"Bowman","year":"2017","journal-title":"Arthritis & Rheumatol. (Hoboken, N.J.)."},{"key":"10.1016\/j.jaut.2019.102364_bib114","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1136\/annrheumdis-2017-212268","article-title":"Effect of rituximab on a salivary gland ultrasound score in primary Sj\u00f6gren\u2019s syndrome: results of the TRACTISS randomised double-blind multicentre substudy","volume":"77","author":"Fisher","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102364_bib115","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1136\/annrheumdis-2012-202293","article-title":"Club Rhumatismes et Inflammations and the French Society of Rheumatology, Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry","volume":"72","author":"Gottenberg","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102364_bib116","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.rdc.2016.03.010","article-title":"New treatment guidelines for sj\u00f6gren\u2019s disease","volume":"42","author":"Vivino","year":"2016","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"10.1016\/j.jaut.2019.102364_bib117","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1093\/rheumatology\/kex375","article-title":"British society for rheumatology standards, guideline and audit working group, the British society for rheumatology guideline for the management of adults with primary sj\u00f6gren\u2019s syndrome","volume":"56","author":"Price","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaut.2019.102364_bib118","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1136\/annrheumdis-2012-202071","article-title":"Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjogren's syndrome: data from a placebo-controlled clinical trial","volume":"72","author":"Pollard","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102364_bib119","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/art.22603","article-title":"BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sj\u00f6gren\u2019s syndrome","volume":"56","author":"Pers","year":"2007","journal-title":"Arthritis Rheum."},{"issue":"Suppl 118","key":"10.1016\/j.jaut.2019.102364_bib120","first-page":"199","article-title":"Double anti-B cell and anti-BAFF targeting for the treatment of primary Sj\u00f6gren\u2019s syndrome","volume":"37","author":"Gandolfo","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jaut.2019.102364_bib121","doi-asserted-by":"crossref","first-page":"817","DOI":"10.4049\/jimmunol.174.2.817","article-title":"Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy","volume":"174","author":"Gong","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2019.102364_bib122","first-page":"490","article-title":"Sequential therapy with belimumab followed by rituximab in Sj\u00f6gren\u2019s syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy","volume":"32","author":"De Vita","year":"2014","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jaut.2019.102364_bib123","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S1074-7613(00)80270-8","article-title":"CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: altered signaling in CD22-deficient mice","volume":"5","author":"Sato","year":"1996","journal-title":"Immunity"},{"key":"10.1016\/j.jaut.2019.102364_bib124","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.4049\/jimmunol.177.5.3063","article-title":"CD22 ligand binding regulates normal and malignant B lymphocyte survival in vivo","volume":"177","author":"Haas","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2019.102364_bib125","series-title":"Ef Fi Cacy and Safety of Epratuzumab in Patients with Moderate\/Severe Active Systemic Lupus Erythematosus\u00a0: Results from EMBLEM , a Phase IIb , Multicentre Study","author":"Wallace","year":"2014"},{"key":"10.1016\/j.jaut.2019.102364_bib126","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/acr.22694","article-title":"Long-term safety and efficacy of epratuzumab in the treatment of moderate-to- severe systemic lupus erythematosus: results from an open-label extension study","volume":"68","author":"Wallace","year":"2016","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.jaut.2019.102364_bib127","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar2018","article-title":"Epratuzumab (humanised anti-CD22 antibody) in primary Sj\u00f6gren\u2019s syndrome: an open-label phase I\/II study","volume":"8","author":"Steinfeld","year":"2006","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2019.102364_bib128","first-page":"763","article-title":"Efficacy of epratuzumab, an anti-CD22 monoclonal IgG antibody","volume":"vol. 70","author":"Gottenberg","year":"2018"},{"key":"10.1016\/j.jaut.2019.102364_bib129","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nri1202","article-title":"The SAP and SLAM families in immune responses and X-linked lymphoproliferative disease","volume":"3","author":"Engel","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jaut.2019.102364_bib130","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1399-0039.2007.00909.x","article-title":"Characterization of mouse CD229 (Ly9), a leukocyte cell surface molecule of the CD150 (SLAM) family","volume":"70","author":"Sintes","year":"2007","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.jaut.2019.102364_bib131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.ai.2014.11.001","article-title":"NOD.H-2h4 mice: an important and underutilized animal model of autoimmune thyroiditis and Sjogren's syndrome","volume":"126","author":"Braley-Mullen","year":"2015","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.jaut.2019.102364_bib132","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.4195.4195","article-title":"An ongoing open-label phase 1\/2 study of INCB050465, a selective PI3K\u03b4 inhibitor, in patients with previously treated B-cell malignancies","volume":"128","author":"Phillips","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2019.102364_bib133","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1136\/annrheumdis-2017-212619","article-title":"Phosphatidylinositol 3-kinase delta pathway: a novel therapeutic target for Sj\u00f6gren\u2019s syndrome","volume":"78","author":"Nayar","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102364_bib134","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1111\/cas.13983","article-title":"Phase I study of tirabrutinib (ONO-4059\/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan","volume":"110","author":"Munakata","year":"2019","journal-title":"Cancer Sci."},{"key":"10.1016\/j.jaut.2019.102364_bib135","first-page":"2015","article-title":"T regulatory and T helper 17 cells in primary Sj\u00f6gren\u2019s syndrome: facts and perspectives","author":"Alunno","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.jaut.2019.102364_bib136","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaut.2013.06.007","article-title":"Interleukin-7: fuel for the autoimmune attack","volume":"45","author":"Dooms","year":"2013","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2019.102364_bib137","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1136\/annrheumdis-2016-209236","article-title":"High soluble IL-7 receptor expression in Sj\u00f6gren\u2019s syndrome identifies patients with increased immunopathology and dryness","volume":"75","author":"Hillen","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102364_bib138","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1002\/art.27318","article-title":"Increased expression of interleukin-7 in labial salivary glands of patients with primary sj\u00f6gren\u2019s syndrome correlates with increased inflammation","volume":"62","author":"Bikker","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.102364_bib139","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1136\/annrheumdis-2011-200744","article-title":"Increased interleukin (IL)-7R\u03b1 expression in salivary glands of patients with primary Sjogren's syndrome is restricted to T cells and correlates with IL-7 expression, lymphocyte numbers and activity","volume":"71","author":"Bikker","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102364_bib140","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1016\/j.bbadis.2018.04.010","article-title":"Anti-IL-7 receptor-\u03b1 treatment ameliorates newly established Sj\u00f6gren\u2019s-like exocrinopathy in non-obese diabetic mice","volume":"1864","author":"Zhou","year":"2018","journal-title":"Biochim. Biophys. Acta (BBA) - Mol. Basis Dis."},{"key":"10.1016\/j.jaut.2019.102364_bib141","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.2353\/ajpath.2009.090319","article-title":"Systemic and local interleukin-17 and linked cytokines associated with Sj\u00f6gren\u2019s syndrome immunopathogenesis","volume":"175","author":"Katsifis","year":"2009","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jaut.2019.102364_bib142","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/ni1263","article-title":"A function for interleukin 2 in Foxp3-expressing regulatory T cells","volume":"6","author":"Fontenot","year":"2005","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jaut.2019.102364_bib143","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2018.01755","article-title":"IL-2 inhibition of Th17 generation rather than induction of treg cells is impaired in primary Sj\u00f6gren\u2019s syndrome patients","volume":"9","author":"Luo","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2019.102364_bib144","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1136\/annrheumdis-2018-213036","article-title":"Short-term and low-dose IL-2 therapy restores the Th17\/Treg balance in the peripheral blood of patients with primary Sj\u00f6gren\u2019s syndrome","volume":"77","author":"Miao","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102364_bib145","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nri3700","article-title":"Ectopic lymphoid-like structures in infection, cancer and autoimmunity","volume":"14","author":"Pitzalis","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jaut.2019.102364_bib146","first-page":"301","article-title":"Biology and signal transduction pathways of the lymphotoxin-\u03b1\u03b2\/LT\u03b2R system, cytokine and growth factor reviews","volume":"22","author":"Remouchamps","year":"2011"},{"key":"10.1016\/j.jaut.2019.102364_bib147","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar3507","article-title":"Lymphotoxin-beta receptor blockade reduces CXCL13 in lacrimal glands and improves corneal integrity in the NOD model of Sj\u00f6gren\u2019s syndrome","volume":"13","author":"Fava","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2019.102364_bib148","first-page":"1470","article-title":"Clinical efficacy and safety of baminercept, a lymphotoxin \u03b2 receptor fusion protein","volume":"vol. 70","author":"StClair","year":"2018"},{"key":"10.1016\/j.jaut.2019.102364_bib149","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nm.3842","article-title":"Homeostatic regulation of T cell trafficking by a B cell-derived peptide is impaired in autoimmune and chronic inflammatory disease","volume":"21","author":"Chimen","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.jaut.2019.102364_bib150","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2018-eular.7486","article-title":"AB0157 Targeting t-cell trafficking in a murine model of sj\u00d6gren\u2019s syndrome","volume":"77","author":"Campos","year":"2018","journal-title":"Ann. Rheum. Dis."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841119307267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841119307267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:27:38Z","timestamp":1760257658000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841119307267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":150,"alternative-id":["S0896841119307267"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2019.102364","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sj\u00f6gren's syndrome: Old and new therapeutic targets","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2019.102364","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102364"}}